US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 14.940
- -0.620-3.98%
Close Dec 10 16:00 ET
- 15.270
- +0.330+2.21%
Pre 08:36 ET
1.28BMarket Cap-4.10P/E (TTM)
15.790High14.570Low3.08MVolume15.790Open15.560Pre Close45.89MTurnover3.89%Turnover RatioLossP/E (Static)85.36MShares25.34052wk High3.48P/B1.18BFloat Cap14.57052wk Low--Dividend TTM79.18MShs Float29.860Historical High--Div YieldTTM7.84%Amplitude3.390Historical Low14.882Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Syndax Pharmaceuticals Stock Forum
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Syndax Pharmaceuticals (SNDX)announced positive topline results from the AUGMENT-101 trial of revumenib in relapsed/refractory mNPM1 AML patients. The trial met its primary endpoint with a 23% complete remission rate (p-value = 0.0014) and achieved a 47% overall response rate in a heavily pre-treated population. The safety profil...
Syndax Pharmaceuticals Inc - Primary Endpoint Met With 23% Cr/CRH Rate in Phase 2 Trial
Dow Jones· 1 min ago
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
No comment yet